Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

By JONEL ALECCIA
AP Health Writer

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths. Wegovy is a high-dose version of the diabetes treatment Ozempic. The latest study tested Wegovy in people without the disease. It’s being praised as a landmark study that could change the way doctors treat heart disease in some patients. The findings could also shift perceptions that a new class of obesity drugs are cosmetic treatments and put pressure on insurers to cover them.